Abstract p21-Activated kinase-1 (Pak1) is frequently upregulated in human breast cancer and is required for transformation of mammary epithelial cells by ErbB2. Here, we show that loss of Pak1, but not the closely related Pak2, leads to diminished expression of b-catenin and its target genes. In MMTV-ErbB2 transgenic mice, loss of Pak1 prolonged survival, and mammary tissues of such mice showed loss of b-catenin. Expression of a b-catenin mutant bearing a phospho-mimetic mutation at Ser 675, a specific Pak1 phosphorylation site, restored transformation to ErbB2-positive, Pak1-deficient mammary epithelial cells. Mice bearing xenografts of ErbB2-positive breast cancer cells showed tumor regression when treated with small-molecule inhibitors of Pak or b-catenin, and combined inhibition by both agents was synergistic. These data delineate a signaling pathway from ErbB2 to Pak to b-catenin that is required for efficient transformation of mammary epithelial cells, and suggest new therapeutic strategies in ErbB2-positive breast cancer. Cancer Res; 73(12); 1-12. Ó2013 AACR.
Introduction
The ErbB2 oncogene is amplified in approximately 30% of human breast cancers and represents a clinically useful therapeutic target (1) . ErbB2 proteins frequently heterodimerize with ErbB1 or ErbB3, and these heterodimers activate a signaling program that drives cell proliferation, resistance to apoptosis, loss of polarity, and increased motility and invasiveness (2) . Key signaling pathways that emanate from ErbB2 include, but are not limited to, the phosphoinositide 3-kinase (PI3K)/Akt/mTOR, Ras/ERK, and Src/Fak networks (3) .
p21-activated kinases (Pak) are Cdc42/Rac-activated serine-threonine protein kinases that regulate the PI3K/Akt, Ras/ ERK, and Src/Fak signaling pathways (4, 5) . Pak1 is required for activation of Akt, perhaps due to a scaffolding function that links Pdk1 to Akt (6, 7) . In Ras/ERK signaling, Pak1 phosphorylates c-Raf at S338 and Mek1 at S298, sites that are required for full activation of these proteins in some cell types (8, 9) . Pak1 also acts downstream in the Src/Fak pathway, as an effector for the small GTPase Rac1 (10, 11) Loss of Pak1, induced by siRNA, expression of dominant-negative alleles, gene disruption, or small-molecule inhibitors, has been shown to block transformation in vitro by oncogenic forms of Kras, ErbB2, and KSHV (9, (12) (13) (14) (15) (16) . In addition, Pak1 is frequently overexpressed in human breast, ovary, bladder, uterine, and brain cancer, due to amplification of the PAK1 gene in an 11q13 amplicon (9) , and has oncogenic properties when expressed in mouse breast epithelial cells and tissues (17, 18) . However, the role of Pak1 in tumorigenesis in vivo, and the particular signaling pathways affected, is not defined. In addition, the apparent special role of Pak1, versus the closely related and broadly expressed Pak2, is not understood.
In this work, we examined the distinct roles of Pak1 and Pak2 in cellular and animal models of ErbB2-driven breast cancer. We found that inhibition of Pak1, but not Pak2, impedes transformation by ErbB2 in a 3-dimensional (3D) cell culture system, but that loss of either Pak1 or Pak2 causes loss of both ERK and Akt activation. A phospho-proteomic screen revealed that Pak1-deficient, but not Pak2-deficient, ErbB2 cells showed almost total loss of b-catenin expression, and that exogenous expression of a stabilized b-catenin or a mutant form bearing a phosphomimic residue at a known site of Pak1 phosphorylation (S675E), restored the ability of ErbB2 to transform Pak1-deficient cells. Finally, we showed that small-molecule inhibitors of Pak or b-catenin blocked transformation by ErbB2 in 3D culture and tumorigenesis by ErbB2 in mouse xenografts. Combined use of anti-Pak and anti-b-catenin agents was synergistic. These findings establish Pak1 as a new target in ErbB2-driven breast cancer and define a new mechanism of action primarily through the b-catenin, but not the ERK or Akt, signaling pathways.
Materials and Methods

Generation of transgenic mice and tumor measurement
All animal experiments were approved by the Fox Chase Cancer Center Institutional Animal Care and Use Committee (IACUC) and carried out according to NIH-approved protocols in compliance with the guide for the Care and Use of Laboratory Animals. Detailed methods are contained in Supplementary Materials and Methods.
Cell lines and 3D cell culture
Tumors from MMTV-Neu:Pak1 þ/þ and MMTV-Neu:Pak1
À/À animals were dissected, rinsed with PBS and minced, then treated with 0.2% collagenase for 2 hours at 37 C. Cells were washed several times with serum-free Dulbecco's Modified Eagle Medium (DMEM), and finally with low calcium medium supplemented with 5% horse serum. Tissues kept in low calcium medium were transferred to T-25 flasks coated with 0.1% gelatin and incubated in a 37 C incubator overnight. The next day, supernatants containing floating cells were transferred and seeded into new flasks and maintained with regular media changes until confluency to prevent fibroblast growth. Fibroblast-free cell populations were derived typically after 6 to 8 weeks. In vitro proliferation was measured by seeding approximately 1 Â 10 5 cells on 0.1% gelatin-coated T25 flasks. At specific time points, cells were trypsinized and counted using Trypan blue exclusion analysis. All analyses used cells passaged less than 6 times.
10A.ErbB2 cells (MCF-10A cells expressing a chimeric form of ErbB2; ref. 19) were maintained in DMEM/F12 (Gibco BRL) supplemented with 5% donor horse serum, 20 ng/mL EGF (Harlan Bioproducts), 10 mg/mL insulin (Sigma), 1 ng/mL cholera toxin (Sigma), 100 mg/mL hydrocortisone (Sigma), 50 U/mL penicillin, and 50 mg/mL streptomycin. For 3D cultures, approximately 5,000 cells were plated atop reconstituted basement membrane (rBM) in 8-well slide chambers as described (19) . To activate chimeric ErbB proteins, 1 mmol/L AP1510 was added to the growth medium. MCF-7, MDA-MB-231, BT-474, and SK-BR3 were obtained from American Type Culture Collection, MCF-7 and MDA-MB-231cells were grown in DMEM supplemented with 10% FBS, BT-474 cells were grown in RPMI supplemented with 10% FBS and SK-BR3 were grown in McCoy's 5A supplemented with 10% FBS. BT-474R cells were a kind gift from Dr. Jose Baselga (Massachusetts General Hospital, Boston, MA).
Tissue preparation, histology, immunohistochemistry, and immunoblotting
All tumor samples and control tissues were fixed overnight in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Hematoxylin and eosin (H&E)-stained sections were used for diagnostic purposes and unstained sections for immunohistochemical studies. Protein concentration was determined, and equal amounts of total proteins were separated on SDS-PAGE. A detailed list of antibodies used is contained in Supplementary Materials and Methods.
Tumor xenografts
All studies described in this article were carried out under approved protocols following Fox Chase Cancer Center IACUC guidelines. Detailed methods are contained in Supplementary Materials and Methods.
Statistical analysis
Statistical analysis was conducted using the unpaired Student t test except for survival curves where the log P rank test was used. Values of P < 0.05 were considered significant.
Results
Pak1, but not Pak2, knockdown inhibits proliferation and rescues apoptosis in 10A.ErbB2 cells
To investigate the roles of Pak1 and Pak2 in ErbB2 signaling, we used doxycycline-inducible short hairpin RNA (shRNA; ref. 15 ). Pak1 and Pak2 are both expressed in MCF10A cells and in ErbB2-positive or ErbB2-negative mammary epithelial cells such as BT-474, SK-BR3, MCF-7, and MDA-MB-231 (Supplementary Fig. S1A ). MCF10A-ErbB2 cells (henceforth termed 10A.ErbB2), which activate ErbB2 in response to AP1510 (19) , were stably transduced with a doxycycline-inducible shRNA specific to Pak1 or Pak2, respectively, and the cells were assessed for proliferation and apoptosis. Upon doxycycline induction, the Pak1 and Pak2 shRNA-infected cells showed specific loss of their intended target (Fig. 1A) . Loss of Pak1, but not Pak2, impeded the proliferation (Fig. 1B) and survival (Fig.  1C ) of 10A.ErbB2 cells, similar results were observed in BT-474, SK-BR3, MCF-7, and MDA-MB-231 ( Supplementary Fig. S1B -S1D). These data suggest that only Pak1 is required for ErbB2 effects on 2 of the cardinal features of transformation: cell division and apoptosis.
Pak1 knockdown restores normal acinar morphology in 3D cell culture
To assess the effects of Pak1 and Pak2 on acinar development and architecture, we plated the shRNA-expressing 10A. ErbB2 cells in a 3D Matrigel matrix. Under such conditions, induction of ErbB2 induces a striking phenotype characterized by formation of multilobular acini (Fig. 1D, a and b) , loss of central apoptosis (Fig. 1D, c and d) , and increase in proliferation (Fig. 1D, e and f) . Expression of Pak1-directed shRNA had little effect on noninduced 10A.ErbB2 cells (Fig. 1D , g, i, and k), but strongly suppressed the transformed phenotype of induced cells (Fig. 1D , h, j, and l). In contrast, Pak2-directed shRNA had little effect on acinar structure irrespective of ErbB2 expression (Fig. 1D, m-r) .
As Pak1 and Pak2 have similar catalytic properties, we sought to uncover differences in their behavior in breast epithelial cells. We and others had earlier established that Pak1 can be driven into the nucleus upon EGF receptor activation in mammary epithelial cells (20, 21) ; we therefore asked whether Pak2 responded in a similar manner. 10A.ErbB2 cells, stably transduced with GFP-Pak1 or GFP-Pak2, were stimulated with EGF or AP1510 for 10 minutes and the distribution of Pak1 and Pak2 determined by immunofluorescence ( Supplementary Fig. S2A-S2C ) and by subcellular fractionation ( Supplementary Fig. S2D ). As expected, a substantial fraction of Pak1 redistributed from the cytoplasm to the nucleus upon EGF or AP1510 stimulation. In contrast, Pak2 was never detected in the nucleus.
Molecular pathways affected by Pak1 and Pak2
Paks have been implicated in regulating ERK signaling downstream of Ras via phosphorylation of Mek1 and c-Raf (5, 12, 22, 23) , and Pak1 has also been implicated in activating Akt via a scaffolding interaction with PDK1 (6, 13) . Given that loss of Pak1, but not Pak2, impeded ErbB2 oncogenic signaling, we asked whether these 2 Pak isoforms affected different signaling pathways. We examined the activation of ERK and Akt in 10A.ErbB2 cells bearing Pak1-or Pak2-specific shRNA. Interestingly, reduction of either Pak1 or Pak2 by shRNA had a profound negative effect on both ERK and Akt activation ( Fig. 2A) . In contrast, expression of a constitutively active form of Pak1 in a panel of breast cancer cell lines had only a modest effect in ERK and Akt activation ( Supplementary Fig. S3A ). This result was expected, as Pak1 is generally thought to be necessary, but not sufficient, for activation of these pathways (4). As ERK and Akt activation was lost in cells depleted of either Pak1 or Pak2, but only Pak1 depletion affected transformation by ErbB2, we used a phospho-antibody array to examine additional signaling pathways that might be differentially regulated by these 2 Pak isoforms. An array containing several dozen ErbB2-relevant phospho-proteinspecific antibodies was probed with lysates from control and Pak1 knockdown 10A.ErbB2 cells. This experiment showed that phosphorylation of a number of known Pak1 direct and indirect substrates, including ERK, c-Raf, BAD, and Akt, were strongly reduced in Pak1 knockdown cells (Fig. 2B) . The protein showing the greatest loss of phosphorylation was b-catenin, a protein that has recently been shown to be stabilized by Pak1-mediated phosphorylation (24, 25) . Immunofluorescence and immunoblot analyses showed a severe reduction in total b-catenin ( Fig. 2C and D 1.E+00
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1.E+04 T r a n s f S h P a k 1 S h P a k 2 N o n T r a n s f S h P a k 1 S h P a k 2 N o n T r a n s f S h P a k 1 S h P a k 2 N o n T r a n s f S h P a k 1 S h P a k 2 b-catenin expression ( Supplementary Fig. S3B ). This loss of b-catenin was accompanied by reduction in almost all known b-catenin target genes (Fig. 2E) , including c-Myc and cyclin D (Fig. 2E) . Similar effects on b-catenin, c-Myc, and cyclin D expression were noted in 10A.ErbB2 cells treated with the Pak inhibitor PF-3758309 ( Supplementary Fig. S3C ).
As relatively few studies have measured the effect of ErbB2 activation on Wnt signaling (27) (28) (29) , we asked whether crossing-linking ErbB2 promoted relocalization of b-catenin from the plasma membrane to the nucleus in human mammary epithelial cells. As a positive control, we treated 10A. ErbB2 cells with Wnt3a, which resulted in relocalization of approximately 50% of the b-catenin to the nucleus within 1 to 2 hours of treatment ( Supplementary Fig. S4A ). Similarly, a substantial amount ($40%) of b-catenin relocalized to the nucleus in response to ErbB2 activation. These results suggest that, in this cell type, ErbB2 activation activates Wnt signaling.
Loss of Pak1 impedes ErbB2-mediated carcinogenesis and is associated with reduced levels of b-catenin in vivo
To determine whether the observed effects of Pak1 in ErbB2 signaling were relevant in vivo, we crossed MMTV-Neu mice with WT and Pak1 À/À mice and followed the natural history of Neu:Pak1 þ/þ and Neu:Pak1 À/À female mice over the course of 2 years. Pak1 deletion is well tolerated in mice, with no effects on general health, longevity, or fertility (30) . Consistent with prior reports (31) , half the MMTV-Neu mice developed palpable breast tumors by 9 months of age (Fig. 3A) . In contrast, the MMTV-Neu/Pak1 À/À mice showed a much longer latency to tumor formation and tumor growth, with half the mice showing detectable disease by 16 months. This result shows that Pak1 negatively affects the progression of ErbB2/Neu-initiated breast cancer in this mouse model. Immunohistochemical staining of tumor tissue revealed strong activity for ErbB2, ERK, Akt, b-catenin, and Pak in Neu:Pak1 þ/þ mice, and almost absent staining for active ERK, Akt, b-catenin, and Pak in Neu:Pak1 À/À mice (Fig. 3B) . These results show that, as in mammary epithelial cell lines ( Fig. 2 and Supplementary Fig. S3 (Fig. 3C) , showed greater viability following treatment with actinomycin D (Fig. 3D) , had greater motility (Fig. 3E , Supplementary Movies S1 and S2), and were more invasive (Fig. 3F) . Role of b-catenin in ErbB2-mediated signaling As Pak1 was required for b-catenin expression in mammary epithelial cells as well as for ErbB2-mediated oncogenesis, we asked whether activators or inhibitors of Wnt signaling affected ErbB2 signaling. We first tested the effects of overexpressing wild-type or a stabilized form of b-catenin (S33Y), as well as a phosphomimetic mutant at the putative Pak1 phosphorylation site (S675E) in 10A.ErbB2 cells (24, 32) . All these forms of b-catenin induced multilobular acini even in the absence of ErbB2 stimulation (Fig. 4A-C) . Conversely, expression of b-catenin S675A, which lacks the Pak1 phosphorylation site, did not on its own induce this multilobular phenotype and blocked the ability of ErbB2 to confer this phenotype. Finally, treatment of cells with a small-molecule inhibitor of Pak or b-catenin blocked formation of aberrant acini in ErbB2-stimulated cells, but the Pak inhibitor did not affect b-catenin S675E-mediated transformation ( Fig. 4E-H) .
In vitro synergy between Pak and b-catenin inhibitors
As Pak1 and b-catenin seem to act in a linked pathway downstream of ErbB2 (Fig. 5A) , we next tested the effects of small-molecule inhibitors of Pak1 and b-catenin, alone and together, on the survival of ErbB2-driven breast cancer cells. These compounds included PF-3758309, which potently suppresses both group A and B Paks (26), iCRT14 and iCRT3, which BT-474 and SK-BR3, respectively), had a nearly identical effect on cell survival. The IC 50 values for iCRT14 in BT-474 and SK-BR3 cells were 71 and 107 nmol/L, respectively; the IC 50 values for iCRT 3 were 52.3 and 82 nmol/L, respectively; whereas the IC 50 values for PF-3758309 were 62.5 and 85.7 nmol/L, respectively (Fig. 5B) . When the compounds were coadministered, however, a marked synergistic effect was noted [combination index (CI) < 0.5; Fig. 5B and Table 1 ]. Coadministration of PF-3758309 and iCRT14 yielded CI values of 13.3 and 20.4 nmol/L respectively, and coadministration of PF-3758309 and iCRT3 yielded CI values of 19.3 and 31 nmol/L respectively, indicating a high degree of synergy. Interestingly, synergistic effects were not seen in cells treated with the tankyrase inhibitor JW55 plus PF-3758309, most likely because b-catenin, once stabilized by phosphorylation at S675, is not readily susceptible to destruction by cleavage. However, the combination of Pak and either of the iCRT b-catenin-targeting agents, which block interactions of b-catenin with TCF, did not merely produce cytostasis, but also resulted in cell death, increasing the frequency of apoptosis by nearly a factor of 2 (Fig. 5C ).
Inhibition of tumor growth by small-molecule inhibitors of Pak and b-catenin
We next tested the effects of these signaling inhibitors on the growth of BT-474 xenografts. BT-474 cells were xenografted to severe combined immunodeficient (SCID) mice and tumors were allowed to form for 7 days. The mice were then treated with vehicle, Pak inhibitor PF-3758309, b-catenin inhibitor iCRT14, or PF-3758309 plus iCRT14, for 15 days. Tumor volumes were assessed every 5 days, at which time the animals were sacrificed.
Treatment with iCRT14 had a marked negative effect on tumor growth, yielding tumors of about one-half the volume, and one-fourth the weight, of tumors in untreated animals ( Fig.  6A-C ). PF-3758309 had an even more dramatic effect, essentially abrogating tumor growth. Interestingly, animals treated with the combined Pak and b-catenin inhibitors showed no tumor growth but also displayed extensive areas of necrosis in tumor remnants (Fig. 6C and E) .
We then assessed signaling activity in these tumor tissues, using immunoblots (Fig. 6D) .
Treatment with the Pak inhibitor reduced Pak activity as expected, whereas treatment with the b-catenin inhibitor did not. Conversely, tumor tissues from iCRT14-treated mice showed loss of b-catenin targets (Myc and cyclin D), but little change in pPak1, pERK, or pAkt. Combined treatment with PF-3758309 and iCRT14 reduced signaling activity in the ERK, Akt, and b-catenin pathways. Analysis of markers of cell proliferation and apoptosis revealed that PF-3758309 treatment prevented cell-cycle progression and induced apoptosis (Fig. 6E) , whereas iCRT14 had a little effect on cell-cycle progression but increased apoptosis. When coadministered, the inhibitors blocked cell-cycle progression and caused extensive apoptosis and necrosis (Fig. 6E) .
Sensitization of trastuzumab-resistant breast cancer cells by Pak and b-catenin inhibitors
As Pak1 and b-catenin seem to act in a linked pathway downstream of ErbB2, we assessed whether blocking these proteins would augment growth inhibition by an anti-ErbB2 agent. For these experiments, we chose the cell line BT-474R, known to be resistant to trastuzumab in vitro (35) . As with parental BT-474 and SK-BR3 cells, we observed a synergistic inhibition of survival when BT-474R cells were treated with Pak plus b-catenin inhibitors (Fig. 7A) . As expected, addition of trastuzumab alone had little effect on these resistant cells (Fig.  7B) . Addition of either the Pak or the b-catenin inhibitor slightly increased apoptosis in BT-474R cells; however, in combination with trastuzumab, these inhibitors increased the number of apoptotic cells to more than 30% and approximately 40%, respectively. When combined, the Pak and b-catenin inhibitors increased apoptosis in BT-474R cells to approximately 15%; this effect was greatly accentuated by the addition of trastuzumab (Fig. 7B) . These results suggest that inhibiting downstream components of ErbB2 signaling such as the Pak/ b-catenin signaling axis, can resensitize trastuzumab-resistant cells to ErbB2-targeted therapeutic antibodies.
Discussion
Pak1 has previously been implicated in breast cancer for the following reasons: the PAK1 gene is frequently amplified in human breast cancer; PAK1 amplification is associated with resistance to tamoxifen; transgenic expression of an activated PAK1 allele induces transformation of mammary epithelial cells in culture and induces breast cancer in mice; and expression of dominant-negative alleles, shRNAs, or treatment with Pak inhibitors, impede the growth and/or normalize the morphology of various breast cancer cell lines in tissue culture (13, (15) (16) (17) (18) . However, none of these studies examined the particular roles of the 2 most highly expressed group A Pak alleles, Pak1 and Pak2, nor did they use clinically relevant inhibitors, nor establish key oncogenic signaling pathways activated by Pak in mouse breast cancer models. Here Of the 6 Pak isoforms, Pak1 in particular has garnered much attention with respect to tumorigenesis, as amplification of the PAK1 gene, with concomitant overexpression of the Pak1 protein, is commonly observed in human cancers of the breast, ovary, and bladder (9) . Unlike other oncogenic serine/threonine protein kinases such as BRAF, activating point mutations, or deletions of PAK1 have not been found in human cancers, despite the ability of activated PAK1 mutants to transform cells in vitro and in vivo. PAK1 gene amplification seems to be particularly relevant in human breast cancer, as it has been shown that such amplification is associated with resistance (36, 37) . In addition, cells bearing such amplifications have recently been shown to be "addicted" to Pak1 signaling, with elevated sensitivity to Pak1 depletion (15) . In contrast, the role of other Paks such as Pak2 in breast cancer is not well established. Pak1 and Pak2 have very similar catalytic properties (38) and, in some cases, share redundant functions. Interestingly, we found that both Pak1 and Pak2 are required for activation of ERK and Akt in 10.ErbB2 cells (Fig. 2) . It is possible that these proteins heterodimerize or, in the case of ERK activation, that each Pak isoform targets a different element in the pathway, for example, one Pak isoform might phosphorylate c-Raf, and the other might phosphorylate Mek. In either event, effects on ERK and Akt signaling cannot explain our observation that loss of Pak1, but not Pak2, impedes ErbB2 oncogenic signaling. Instead, our results suggest that other pathways, such as the Wnt/b-catenin pathway, are more likely to mediate these effects, as only Pak1 depletion affects b-catenin levels and b-catenin target gene transcription in the cell types we examined. Why is Pak1 unique in this respect? Although the catalytic properties of Pak1 and Pak2 are indistinguishable in vitro, the 2 proteins localize differently (39, 40) . For example, Pak1 is driven into the nucleus following EGF stimulation of MCF-7 and MDA-MB-435 human breast cancer cells (20) and in MCF10A cells (Supplementary Fig. S2 ; ref. 21 ), whereas Pak2 is not (Supplementary Fig. S2 ). In addition, the effects of gene deletion are quite different for Pak1 and Pak2: deletion of the former is associated with a mild phenotype, whereas deletion of the latter results in early embryonic lethality (8) . Why Pak1, but not Pak2, affects b-catenin levels in mammary epithelial cells is unknown, and it will be of interest to determine whether these different behaviors reside in different intrinsic substrate selection or differences in the noncatalytic, N-terminalregulatory domains of these kinases.
The role of the Wnt/b-catenin pathway in ErbB2 signaling in breast cancer is incompletely understood. In general, ErbB2 positivity in breast cancer is associated with a luminal phenotype, whereas Wnt activation is more commonly associated with a basal phenotype (41) . However, multiple lines of evidence suggest important links between ErbB2 and b-catenin signaling. First, ErbB2 physically associates with b-catenin, and such complexes are associated with human infiltrating ductal breast and also with MMTV-c-Neu and MMTV-Wnt-1 mouse models of breast cancer (28) . Second, ErbB2 phosphorylates b-catenin at Tyr 654, leading to dissociation of the E-cadherin-b-catenin membrane complex and increased signaling to Wnt target genes such as cyclin D1 (29) . In addition, ErbB2 has been reported to transcriptionally activate expression of the Wnt pathway target gene Jab1 via an Akt/b-catenin pathway in breast cancer cells (42) . These observations are supported by recent publications showing a positive correlation between HER2/neu expression and nucleocytoplasmic (i.e., non-plasma membrane) b-catenin in nodepositive carcinomas (P ¼ 0.02) and in HER2/neu-induced mouse mammary tumors, with activation of Wnt pathway genes (27) , as well as eradication of breast tumor-initiating cells by pharmacologic inhibitors of Wnt/b-catenin signaling in this mouse model (43) .
Recently, it has been reported that Pak1 has a direct role in b-catenin stabilization in colon cancer cells, via phosphorylation of b-catenin at Ser 675 (24, 44) and Ser 663/675 (45). As we have previously shown that ErbB2 activates Pak1 (16), we here propose that Pak1 is a required signaling element linking ErbB2 activation to b-catenin in mammary epithelial cells, and that such activation is necessary for oncogenesis. This view is supported by the loss of b-catenin and target gene activation in Pak1-depleted mammary epithelial cells or Pak1-deleted mammary tissue, and the blockade of tumor growth by Pak or b-catenin inhibition seen in animals xenografted with ErbB2-positive tumor cells.
Small-molecule Pak inhibitors have recently entered clinical trials and it should soon be possible to evaluate the potential of such agents in human cancer. We suggest that such agents may be useful in 2 general settings: cancers that have 11q13 amplification, such as a large fraction of breast, ovarian, 
